Therapy Areas: Vaccines
GSK and SK Bioscience' submit COVID-19 vaccine for approval in South Korea
29 April 2022 -

British healthcare company GlaxoSmithKline's (GSK) (LON:GSK) COVID-19 vaccine candidate, developed with SK Bioscience Co Ltd (KRX:302440), a South Korean vaccine and biopharmaceutical company, has been submitted for regulatory approval in South Korea after positive Phase III clinical data, Reuters news agency reported on Friday.

GSK said that SK bioscience will also apply to the World Health Organisation (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world.

According to GSK, an extended clinical trial is planned to test the vaccine's effectiveness against the Omicron COVID-19 variant.